Nearly half of American adults have diabetes or prediabetes; more than 30 million adults and children have diabetes; and every 21 seconds, another individual is diagnosed with diabetes in the U.S. Founded in 1940, the American Diabetes Association (ADA) is the nation’s leading voluntary health organization whose mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. The ADA drives discovery by funding research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and works to safeguard policies and programs that protect people with diabetes. In addition, the ADA supports people living with diabetes, those at risk of developing diabetes, and the health care professionals who serve them through information and programs that can improve health outcomes and quality of life. For more information, please call the ADA at 1-800-DIABETES (1-800-342-2383) or visit Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn)

Clinical psychologists have studied psychology at University, usually for at least seven years. They have specialised in learning about how the feelings, actions, beliefs, experiences and culture of people affect the way they live. They have learned how to listen to and understand people’s emotional and psychological problems and how to help people make changes in their lives.
-Keep your blood pressure under control. The same lifestyle changes that control blood glucose levels (dietary modifications and exercise) may also help you keep your blood pressure at safe levels. The American Diabetes Association recommends that people with diabetes keep their blood pressure below 140/80, but check with your health care professional about what target is best for you.
In relation to perceptions and beliefs about diabetes, a significant reduction in illness identity (how much patients experience diabetes related symptoms) on the BIPQ was observed in favour of the intervention (adjusted mean difference −0.54 (95% confidence interval −1.04 to −0.03), P=0.04). However, we saw no significant group differences for perceptions of consequences, timeline, control, concern, emotions, and illness comprehensibility. A significant improvement in health status on the EQ-5D VAS was observed in favour of the intervention (4.38 (0.44 to 8.33), P=0.03) but no significant differences were observed between groups for the quality of life index score. Finally, the measure of perceived support for diabetes management showed a significant improvement between the groups in how supported the participants felt in relation to their diabetes management overall (0.26 (0.03 to 0.50), P=0.03) but no significant group differences on appraisal, emotional, and informational support.

The incidence of type 1 diabetes was higher in New Zealand Europeans than other ethnic groups throughout the study period (Figure 2, p<0.0001). There was little difference in incidence among non-European ethnic groups. The annual incidences (per 100,000) by 2009 were: Europeans 32.5 (95% CI 23.8–43.3), Non-Europeans 14.4 (95% CI 9.2–21.4), Maori 13.9 (95% CI 5.2–29.7), Pacific Islanders 15.4 (95% CI 7.3–28.5), and Other 13.5 (95% CI 5.8–26.8). The rate of increase in incidence over the study period was very similar across all ethnicities, as illustrated by the slopes in Figure 2. However, while the average increase in incidence was higher for Europeans than Non-Europeans in children of all age groups (Table 1), the increase was proportionally lower in Europeans (2-fold) than Non-Europeans (3-fold) due to a lower baseline incidence in the latter group (Figure 2). Nonetheless, in both ethnic groups type 1 diabetes incidence in children 10–14 yr increased at a higher rate than in the youngest 0–4 yr group, with a >2-fold difference observed among both Europeans and Non-Europeans (Table 1). Age at diagnosis across the study period was similar in both ethnic groups (p = 0.47).

We are now operating as a Branch of Diabetes New Zealand; previously we had been in operation for more than 30 years, as an independent Incorporated Society. During that time, we have seen some significant changes in the field of diabetes. As times change, we strive to change with them, but our basic mission remains the same: to support the interests of people living with diabetes in the Rotorua region.

Of the 189 responders (35.0% response rate) to the patient survey, 19.6% (37/189) had used a diabetes app. App users were younger and in comparison to other forms of diabetes mellitus, users prominently had type 1 DM. The most favored feature of the app users was a glucose diary (87%, 32/37), and an insulin calculator was the most desirable function for a future app (46%, 17/37). In non-app users, the most desirable feature for a future app was a glucose diary (64.4%, 98/152). Of the 115 responders (40.2% response rate) to the HPs survey, 60.1% (68/113) had recommended a diabetes app. Diaries for blood glucose levels and carbohydrate counting were considered the most useful app features and the features HPs felt most confident to recommend. HPs were least confident in recommending insulin calculation apps.
To assess whether changes in incidence were more marked in certain age groups (as observed overseas [3], [4]), patients were also categorised into three bands according to age at diagnosis: 0–4 yr (children less than 5 yr), 5–9 yr (equal or greater than 5 yr but less than 10 yr), and 10–14 yr (equal or greater than 10 yr but less than 15 yr). These age bands also match national census classifications. The incidence of type 1 diabetes was assessed as the number of new diagnoses per 100,000 age-matched inhabitants on a given year, based on the 5-yearly national census data from Statistics New Zealand [12] and interpolated estimates of the population for the intervening years. Incidence was modelled using the Poisson distribution. Point estimates were calculated with exact Poisson confidence limits, and change in incidence over time were analysed using Poisson regression. Changes in patient numbers, age at diagnosis, and anthropometric data over time were assessed by linear regression. Poisson modelling was undertaken using StatsDirect v2.7.8 (StatsDirect Ltd, UK); other analyses were undertaken using JMP v. 5.1 (SAS Inc, USA).
The annual incidence of type 1 diabetes in children <15 yr in the Auckland population in 1990–2009 was 16.4/100,000 (95% CI 15.3–17.5). Considering the underlying 36% population growth over the 1990–2009 period, there was still a progressive increase in the incidence of new cases (p<0.0001; Figure 1A). By Poisson regression the type 1 diabetes incidence in children <15 yr in 2009 was 22.5 per 100,000 (95% CI 17.5–28.4), in comparison to 10.9 per 100,000 in 1990 (95% CI 7.0–16.1) (Figure 1A). Overall incidence among males and females across the 20-year period was similar (p = 0.49). The increase in incidence was greatest among children 10–14 yr (average increase of +0.81/year; p<0.0001) and lowest among children 0–4 yr (+0.32/year; p = 0.02); incidences by 2009 were 27.0 (95% CI 18.1–38.8) for children 10–14 yr, 25.4 (95% CI 16.5–37.3; +0.66/year; p = 0.0002) for children 5–9 yr, and 14.9 per 100,000 (95% CI 8.4–24.5) for those aged 0–4 yr (Figure 1B).
Diabetes is a metabolic disorder, which is accompanied by high blood glucose levels. It is a result of improper functioning of the pancreas, which secretes the insulin hormone. Lack of insulin, result in ketoacidosis. Makhana or Fox nut is a sweet and sour seed, which is also known as Euryale ferox. These seeds contain starch and ten percent of protein. There is no supporting literature for its positive association with diabetes. Therapeutic effects of fox nut involve its strengthening of kidney. It also helps to relieve the dampness, associated with leucorrhoea. It also regulates hypertension or high blood pressure. It is also beneficial for individuals with impotence and arthritis. Fox nuts are effective for individuals with high risk of premature ageing. It is also known as gorgon nut, is also helpful.